clinical trial · NCT06110676
A Study to Evaluate the Efficacy and Safety of LZM012
PsoriasisLZM012Secukinumab
brief summary
This study is a muti-center, randomized, double blind, positive control phase III clinical study to evaluate the efficacy and safety of LZM012 in moderate to severe chronic plaque psoriasis patients
started
Aug 21, 2023
primary completion
Apr 1, 2025
completion
Jun 1, 2025
last updated
Nov 1, 2023
official title
A Muti-center, Randomized, Double Blind, Positive Control Phase III Clinical Study to Evaluate the Efficacy and Safety of LZM012 in Moderate to Severe Chronic Plaque Psoriasis Patients
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol